Medivir AB

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0020181014
SEK
2.44
0.04 (1.67%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Poor long term growth as Net Sales has grown by an annual rate of -9.37% over the last 5 years

 
2

The company has declared Negative results for the last 3 consecutive quarters

3

Risky -

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 1,309 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.45

stock-summary
Return on Equity

-35.69%

stock-summary
Price to Book

4.95

Revenue and Profits:
Net Sales:
6 Million
(Quarterly Results - Dec 2025)
Net Profit:
-43 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
533.77%
0%
533.77%
6 Months
57.01%
0%
57.01%
1 Year
75.54%
0%
75.54%
2 Years
-14.04%
0%
-14.04%
3 Years
-61.82%
0%
-61.82%
4 Years
-62.49%
0%
-62.49%
5 Years
-64.96%
0%
-64.96%

Medivir AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-9.37%
EBIT Growth (5y)
-8.36%
EBIT to Interest (avg)
-78.25
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.34
Sales to Capital Employed (avg)
0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.77
EV to EBIT
-0.24
EV to EBITDA
-0.24
EV to Capital Employed
0.56
EV to Sales
5.84
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-239.86%
ROE (Latest)
-122.99%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 450.00% vs -77.27% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -61.80% vs -31.53% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5.50",
          "val2": "1.00",
          "chgp": "450.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.90",
          "val2": "-26.40",
          "chgp": "54.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-43.20",
          "val2": "-26.70",
          "chgp": "-61.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-7,709.10%",
          "val2": "-27,100.00%",
          "chgp": "1,939.09%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 142.86% vs -53.95% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 23.44% vs -38.07% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8.50",
          "val2": "3.50",
          "chgp": "142.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-60.00",
          "val2": "-125.00",
          "chgp": "52.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.80",
          "val2": "0.80",
          "chgp": "125.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "4.70",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-94.40",
          "val2": "-123.30",
          "chgp": "23.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-10,882.40%",
          "val2": "-36,636.70%",
          "chgp": "2,575.43%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoYstock-summary

Dec'25
Dec'24
Change(%)
Net Sales
5.50
1.00
450.00%
Operating Profit (PBDIT) excl Other Income
-11.90
-26.40
54.92%
Interest
0.70
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-43.20
-26.70
-61.80%
Operating Profit Margin (Excl OI)
-7,709.10%
-27,100.00%
1,939.09%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Dec 2025 is 450.00% vs -77.27% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -61.80% vs -31.53% in Dec 2024

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
8.50
3.50
142.86%
Operating Profit (PBDIT) excl Other Income
-60.00
-125.00
52.00%
Interest
1.80
0.80
125.00%
Exceptional Items
0.00
4.70
-100.00%
Consolidate Net Profit
-94.40
-123.30
23.44%
Operating Profit Margin (Excl OI)
-10,882.40%
-36,636.70%
2,575.43%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 142.86% vs -53.95% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 23.44% vs -38.07% in Dec 2024

stock-summaryCompany CV
About Medivir AB stock-summary
stock-summary
Medivir AB
Pharmaceuticals & Biotechnology
Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.
Company Coordinates stock-summary
Company Details
Lunastigen 7 , HUDDINGE None : 141 44
stock-summary
Tel: 46 8 5468310046 8 54683100
stock-summary
Registrar Details